Fusion Pharmaceuticals Inc.
FUSNDelisted Jun 5, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001805890
Fusion Pharmaceuticals Inc. was delisted on Jun 5, 2024; its insiders filed their last Form 4 on Jun 4, 2024; 114 institutions reported holding it in 13F filings for Q1 2024, worth $1.47B in total; Duquesne Family Office was the only superinvestor holding it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 114
- Q1 2024, +37 vs. previous quarter
- 13F value
- $1.47B
- Reported value at the end of Q1 2024
- Superinvestors holding
- 1
- At the end of Q1 2024
Superinvestors holding FUSN, Q1 2024
1 superinvestor reports holding Fusion Pharmaceuticals Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Duquesne Family Office
Stanley Druckenmiller
0.2%
Fusion Pharmaceuticals Inc.'s share of the portfolio
- Shares
- 399,748
- Value
- $8.52M
Latest insider trades
Open-market purchases and sales by Fusion Pharmaceuticals Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 11, 2022 (view filing) | Aug 11 | Same day | Gannon StevenDirector | PPurchase | +44.4K | $2.03 | +$90.1K | +370.0%56.4K after | |
| Apr 27, 2022 (view filing) | Apr 25-27 | 2 days | Valliant JohnChief Executive Officer | SSale | −8.69K | $6.04 | −$52.5K | −2.7%318.1K after | 3 lots |
| Apr 22, 2022 (view filing) | Apr 20-21 | 2 days | Valliant JohnChief Executive Officer | SSale | −1.29K | $6.01 | −$7.75K | −0.4%326.8K after | 2 lots |
| Apr 13, 2022 (view filing) | Apr 11-13 | 2 days | Valliant JohnChief Executive Officer | SSale | −32.8K | $6.87 | −$225.7K | −9.1%328.1K after | 3 lots |
| Apr 8, 2022 (view filing) | Apr 6-8 | 2 days | Valliant JohnChief Executive Officer | SSale | −2.18K | $7.55 | −$16.5K | −0.6%361.0K after | 3 lots |
| Apr 5, 2022 (view filing) | Apr 1-5 | 4 days | Valliant JohnChief Executive Officer | SSale | −3.80K | $7.72 | −$29.3K | −1.0%363.2K after | 3 lots |
| Apr 1, 2022 (view filing) | Mar 30 | 2 days | Valliant JohnChief Executive Officer | SSale | −300 | $7.52 | −$2.26K | −0.1%367.0K after | |
| Mar 29, 2022 (view filing) | Mar 25-29 | 4 days | Valliant JohnChief Executive Officer | SSale | −10.3K | $7.54 | −$77.7K | −2.7%367.3K after | 3 lots |
| Mar 24, 2022 (view filing) | Mar 21-23 | 3 daysLate | Valliant JohnChief Executive Officer | SSale | −4.80K | $7.52 | −$36.1K | −1.3%377.6K after | 3 lots |
| Mar 21, 2022 (view filing) | Mar 17-21 | 4 days | Valliant JohnChief Executive Officer | SSale | −3.60K | $7.53 | −$27.1K | −0.9%382.4K after | 3 lots |
Top 10 13F holders, Q1 2024
The largest institutional positions in Fusion Pharmaceuticals Inc. at the end of Q1 2024; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Federated Hermes, Inc. | 10,811,153 | $230.5M | 0.53% | −75,000−0.7% | Reduced |
| Perceptive Advisors LLC | 6,825,395 | $145.5M | 2.56% | +4,074,000+148.1% | Added |
| Avidity Partners Management LP | 6,500,328 | $138.6M | 4.93% | 00.0% | Unchanged |
| Deerfield Management Company, L.P. (Series C) | 6,401,000 | $136.5M | 2.37% | 00.0% | Unchanged |
| FIL Ltd | 4,187,271 | $89.3M | 0.09% | +4,187,271 | New |
| Pentwater Capital Management LP | 3,781,778 | $80.6M | 1.32% | +3,781,778 | New |
| Johnson & Johnson | 3,670,516 | $78.3M | 1.77% | 00.0% | Unchanged |
| Canada Pension Plan Investment Board | 3,116,966 | $66.5M | 0.07% | 00.0% | Unchanged |
| TPG GP A, LLC | 2,551,794 | $54.4M | 1.04% | 00.0% | Unchanged |
| FMR LLC | 1,836,739 | $39.2M | 0.00% | −3,476,555−65.4% | Reduced |